Danaher Co. (NYSE:DHR) Shares Acquired by Concentric Capital Strategies LP

Concentric Capital Strategies LP boosted its position in Danaher Co. (NYSE:DHR) by 203.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,182 shares of the conglomerate’s stock after acquiring an additional 4,815 shares during the quarter. Concentric Capital Strategies LP’s holdings in Danaher were worth $1,997,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in DHR. Lynx Investment Advisory purchased a new position in Danaher in the second quarter valued at $63,000. Harbor Capital Advisors Inc. increased its holdings in shares of Danaher by 8.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 11,505 shares of the conglomerate’s stock valued at $2,875,000 after acquiring an additional 879 shares during the last quarter. Park Avenue Securities LLC raised its position in shares of Danaher by 2.3% during the 2nd quarter. Park Avenue Securities LLC now owns 25,551 shares of the conglomerate’s stock worth $6,384,000 after acquiring an additional 581 shares in the last quarter. CWM LLC lifted its stake in Danaher by 5.1% during the second quarter. CWM LLC now owns 23,034 shares of the conglomerate’s stock worth $5,755,000 after purchasing an additional 1,122 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its holdings in Danaher by 5.5% in the second quarter. Valeo Financial Advisors LLC now owns 14,053 shares of the conglomerate’s stock valued at $3,511,000 after purchasing an additional 729 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.7 %

Shares of Danaher stock opened at $241.27 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a market cap of $174.26 billion, a price-to-earnings ratio of 46.04, a price-to-earnings-growth ratio of 4.41 and a beta of 0.85. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The company’s 50-day simple moving average is $254.59 and its 200-day simple moving average is $259.41.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business posted $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, equities research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DHR. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Royal Bank of Canada decreased their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.